Braidwell »

Surrozen shares owned by Braidwell

Quarter-by-quarter ownership of Surrozen (SRZN) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Surrozen

Tip: Access up to 7 years of quarterly data

All positions including Surrozen held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Surrozen by Braidwell

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.8M 140k 12.89
2025-06-30 $1.3M 140k 8.94

More positions owned by Braidwell

Guardant Health Debt 1.250% 2/1 (Principal)
Caris Life Sciences (CAI)
Novocure Note 11/0 (Principal)
Xenon Pharmaceuticals (XENE)
Cg Oncology (CGON)
Neurocrine Biosciences (NBIX)
Repligen Corp Note 1.000%12/1 (Principal)
Krystal Biotech (KRYS)
Nuvalent Inc-a (NUVL)
Neogenomics Note 0.250% 1/1 (Principal)
Soleno Therapeutics (SLNO)
Irhythm Technologies Note 1.500% 9/0 (Principal)
Edgewise Therapeutics (EWTX)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Inspire Med Sys (INSP)

View all positions for Braidwell

Top funds holding Surrozen

Stempoint Capital
VR Adviser
RA Capital Management
5AM Venture Management
Vanguard Group
Vivo Capital
Stonepine Capital Management
Samsara BioCapital
Nantahala Capital Management
Longwood Capital Partners
Braidwell
Regents of the University of California
Millennium Management
Adage Capital Partners GP
Euclidean Capital

View all funds holding Surrozen